Cargando…

PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes

SIMPLE SUMMARY: We compared RNA next-generation sequencing (RNA-seq) to standard immunohistochemistry (IHC) for PD-L1 expression measurement and associations with pembrolizumab immunotherapy outcomes in NSCLC patient tumors. RNA-seq and IHC PD-L1 score interpretation agreed for 80% of patients, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nesline, Mary K., Previs, Rebecca A., Dy, Grace K., Deng, Lei, Lee, Yong Hee, DePietro, Paul, Zhang, Shengle, Meyers, Nathan, Severson, Eric, Ramkissoon, Shakti, Pabla, Sarabjot, Conroy, Jeffrey M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571724/ https://www.ncbi.nlm.nih.gov/pubmed/37835483 http://dx.doi.org/10.3390/cancers15194789

Ejemplares similares

PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab
por: George, Saby, et al.
Publicado: (2018)

Cancer immunity marker RNA expression levels across gynecologic cancers: Implications for immunotherapy
por: Jou, Jessica, et al.
Publicado: (2023)

Immune profiling and immunotherapeutic targets in pancreatic cancer
por: Lenzo, Felicia L., et al.
Publicado: (2021)

Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response
por: Pabla, Sarabjot, et al.
Publicado: (2021)

LAG‐3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics
por: Adashek, Jacob J., et al.
Publicado: (2023)

A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors
por: Conroy, Jeffrey M., et al.
Publicado: (2021)

T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy
por: Miyashita, Hirotaka, et al.
Publicado: (2023)

Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy
por: Czajka-Francuz, Paulina, et al.
Publicado: (2023)

Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay
por: Pabla, Sarabjot, et al.
Publicado: (2019)

PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation
por: Keppens, Cleo, et al.
Publicado: (2020)

Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing
por: Dy, Grace K., et al.
Publicado: (2019)

Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry
por: Huang, Richard S. P., et al.
Publicado: (2021)

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer
por: Roach, Charlotte, et al.
Publicado: (2016)

Concordance of Immunohistochemistry-Based and Gene Expression-Based Subtyping in Breast Cancer
por: Holm, Johanna, et al.
Publicado: (2020)

Tumor Inflammation, Obesity, and Proliferative Status as Biomarkers in Gastroesophageal Adenocarcinoma
por: Mukherjee, Sarbajit, et al.
Publicado: (2021)

Concordance between Histology, Immunohistochemistry, and RT-PCR in the Diagnosis of Feline Infectious Peritonitis
por: Stranieri, Angelica, et al.
Publicado: (2020)

Utility of Immunohistochemistry and ETV6 (12p13) Gene Rearrangement in Identifying Secretory Carcinoma of Salivary Gland among Previously Diagnosed Cases of Acinic Cell Carcinoma
por: Naous, Rana, et al.
Publicado: (2017)

Standardization of PD-L1 immunohistochemistry
por: Martinez-Morilla, Sandra, et al.
Publicado: (2021)

Oncologist uptake of comprehensive genomic profile guided targeted therapy
por: Nesline, Mary K., et al.
Publicado: (2019)

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
por: Conroy, Jeffrey M., et al.
Publicado: (2019)

Concordance of RT-qPCR with immunohistochemistry and its beneficial role in breast cancer subtyping
por: Li, Yilun, et al.
Publicado: (2023)

Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer
por: Xu, Haipeng, et al.
Publicado: (2017)

Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy
por: Hu, Weixian
Publicado: (2019)

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
por: Morrison, Carl, et al.
Publicado: (2018)

PD-L1 testing by immunohistochemistry in immuno-oncology
por: Vranic, Semir, et al.
Publicado: (2023)

The Three P's: Parotid, PD-L1, and Pembrolizumab
por: Wiggins, Amanda, et al.
Publicado: (2019)

Investigation of Molecular Interactions Mechanism of Pembrolizumab and PD-1
por: Wang, Simiao, et al.
Publicado: (2023)

Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC
por: Patnaik, Santosh K., et al.
Publicado: (2021)

Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
por: Sharma, Meenal, et al.
Publicado: (2019)

Determination of the HER2 amplification status by in situ fluorescent hybridization and concordance with immunohistochemistry for breast cancer samples in Colombia
por: Plata, Adriana, et al.
Publicado: (2013)

Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry
por: Stefanovic, Stefan, et al.
Publicado: (2017)

Concordance between cryobiopsy and forceps biopsy specimens in assessment of immunohistochemistry staining for non-small cell lung carcinoma
por: Nishimatsu, Kanako, et al.
Publicado: (2023)

Mismatch Repair Protein Expression in Endometrial Cancer: Assessing Concordance and Unveiling Pitfalls in Two Different Immunohistochemistry Assays
por: Yoshida, Hiroshi, et al.
Publicado: (2023)

Next-Generation Sequencing in Order to Better Characterize a BRCA Variant of Uncertain Significance
por: Sorscher, Steven, et al.
Publicado: (2017)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy
por: Möhn, Nora, et al.
Publicado: (2021)

Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression
por: Huang, Richard S.P., et al.
Publicado: (2021)

PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC
por: Wu, Chiao-En, et al.
Publicado: (2020)

Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
por: Isaacs, James, et al.
Publicado: (2020)

Pembrolizumab Induces an Unexpected Conformational Change in the CC′-loop of PD-1
por: Roither, Bernhard, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f14eh22jlbvkl3flb45033h3l7